The gap between real ‐world and guidelines in the use of sodium–glucose cotransporter 2 inhibitors for heart failure patients with reduced ejection fraction: Is it underestimated or overestimated? Letter regarding the article ‘Real‐world use of sodium–glucose cotransporter 2 inhibitors in patients with heart f ailure and reduced ejection fraction: Data from the Swedish Heart Failure Registry’